InMed Pharmaceuticals Inc. Annual Operating Income (Loss) in USD from 2021 to 2023

Taxonomy & unit
us-gaap: USD
Description
The net result for the period of deducting operating expenses from operating revenues.
Summary
InMed Pharmaceuticals Inc. quarterly/annual Operating Income (Loss) history and growth rate from 2021 to 2023.
  • InMed Pharmaceuticals Inc. Operating Income (Loss) for the quarter ending September 30, 2023 was -$2.54M, a 27.7% increase year-over-year.
  • InMed Pharmaceuticals Inc. Operating Income (Loss) for the twelve months ending September 30, 2023 was -$6.97M, a 63.6% increase year-over-year.
  • InMed Pharmaceuticals Inc. annual Operating Income (Loss) for 2023 was -$7.95M, a 57.3% increase from 2022.
  • InMed Pharmaceuticals Inc. annual Operating Income (Loss) for 2022 was -$18.6M, a 82.3% decline from 2021.
Operating Income (Loss), Trailing 12 Months (USD)
Operating Income (Loss), Annual (USD)
Operating Income (Loss), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2023 -$7.95M +$10.7M +57.3% Jul 1, 2022 Jun 30, 2023 10-K 2023-09-29
2022 -$18.6M -$8.4M -82.3% Jul 1, 2021 Jun 30, 2022 10-K 2023-09-29
2021 -$10.2M Jul 1, 2020 Jun 30, 2021 10-K 2022-09-23
* An asterisk sign (*) next to the value indicates that the value is likely invalid.